2023-09-12 15:18:33
The tyrosine kinase inhibitor (TKI) osimertinib is already used in the first line for advanced non-small cell lung cancer (NSCLC) with EGFR mutation (EGFRm). Now, for the first time, it has been examined whether the combination with chemotherapy shows a benefit. The answer is yes, albeit with side effects.
Trsakaoe/AdobeStock
The tyrosine kinase inhibitor (TKI) osimertinib is used as first-line therapy in advanced EGFRm NSCLC due to its superior progression-free survival (PFS) and overall survival (OS) data. The third-generation TKI inhibits EGFR-T790M resistance mutations and is also effective in central nervous system (CNS) metastases. However, even with osimertinib, many patients experience further progression of the tumor disease. Data on first-generation TKIs show an improvement in efficacy when chemotherapy is added. There are currently no such data for osimertinib.
The open-label, randomized phase III study, FLAURA2, aimed to evaluate the efficacy and safety of osimertinib plus chemotherapy in the first-line setting compared to osimertinib monotherapy in advanced EGFRm NSCLC. A total of 557 patients took part in the study. They were treated with either osimertinib plus chemotherapy (osimertinib 80mg once daily [QD] + Pemetrexed 500mg/m2 + Cisplatin 75mg/m2 or Carboplatin AUC5 for 4 cycles every 3 weeks [Q3W]followed by osimertinib 80mg QD + pemetrexed 500mg/m2 Q3W) or treated with osimertinib monotherapy (80mg QD) until progression/discontinuation criteria.
To view the content you must log in or register.
1694565323
#line #advanced #EGFRm #NSCLC
